Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: Potential role of nonimmunological mechanisms

Annals of the New York Academy of Sciences

Volumn 1028, Issue , 2004, Pages 340-350

  Chang, Chien Chung ^a   Campoli, Michael ^a   Luo, Wei ^a   Zhao, Wanzhou ^a   Zaenker, Kurt S ^b   Ferrone, Soldano ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Extracellular matrix; Focal adhesion kinase; Melanoma; Proteoglycan

Indexed keywords

FOCAL ADHESION KINASE; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MK2 23; PROTEIN P130; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMORAL IMMUNITY; MELANOMA; METASTASIS; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 14944357681     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1322.040     Document Type: Conference Paper

References (38)

1. LIN, T.S., M.S. LUCAS & J.C. BYRD. 2003. Rituximab in B-cell chronic lymphocytic leukemia. Semin. Oncol. 30: 483-492.
2. DILLMAN, R.O. 2003. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin. Oncol. 30: 434-447.
3. BASELGA, J. 2000. Clinical trials of single-agent trastuzumab (Herceptin). Semin. Oncol. 27: 20-26.
4. BASELGA, J. & J. ALBANELL. 2001. Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12: S35-41.
5. SMITH, M.R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368.
6. LIN, C.C., Y.C. SHEN, C.K. CHUANG, et al. 2001. Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells. Adv. Exp. Med. Biol. 491: 419-429.
7. MITTELMAN, A., Z.J. CHEN, H. YANO, et al. 1992. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA 89: 466-470.
8. KUSAMA, M., T. KAGESHITA, Z.J. CHEN, et al. 1989. Characterization of syngeneic anti-idiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J. Immunol. 143: 3844-3852.
9. GIACOMINI, P., P.O. NATALI & S. FERRONE. 1985. Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J. Immunol. 135: 696-702.
10. FERRONE, S., P. GIACOMINI, P.O. NATALI, et al. 1983. A human high molecular weight-melanoma associated antigen (HMW-MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma. In Proceedings of the First International Symposium on Neutron Capture Therapy: 174-183. Brookhaven National Laboratory. Associated Universities, Inc. Brookhaven, NY.
11. NATALI, P.O., P. GIACOMINI, C. RUSSO, et al. 1983. Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma associated antigens. J. Cutan. Pathol. 10: 225-237.
12. NATALI, P.O., K. IMAI, B.S. WILSON, et al. 1981. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J. Natl. Cancer Inst. 67: 591-601.
13. MARINCOLA, P.M., E.M. JAFFEE, D.J. HICKLIN, et al. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74: 181-273.
14. SCHUURHUIS, D.H., A. IOAN-FACSINAY, B. NAGELKERKEN, et al. 2002. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J. Immunol. 168: 2240-2246.
15. GIACOMINI, P., F. VEGLIA, P. CORDIALI FEI, et al. 1984. Level of a membrane bound high molecular weight melanoma associated antigen and a cytoplasmic melanoma associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res. 44: 1281-1287.
16. IMAI, K., M. A. PELLEGRINO, B.S. WILSON, et al. 1982. Higher cytolytic efficiency of an IgG2a than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. Cell. Immunol. 72: 239-247.
17. WANG, S.C., L. ZHANG, G.N. HORTOBAGYI & M.C. HUNG. 2001. Targeting HER2: recent developments and future directions for breast cancer patients. Semin. Oncol. 28: 21-29.
18. SMITH, M.R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 22: 7359-7368.
19. BOGENRIEDER T. & M. HERLYN. 2003. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22: 6524-6536.
20. HARPER, J.R. & R.A. REISFELD. 1983. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J. Natl. Cancer Inst. 71: 259-263.
21. DE VRIES, J.E., G.D. KEIZER, A.A. TE VELDE, et al. 1986. Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int. J. Cancer 38: 465-473.
22. CHATTOPADHYAY, P., J. STARKEY, W.J. MORROW, et al. 1992. Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA 89: 2684-2688.
23. KAGESHITA, T., N. KURIYA, T. ONO, et al. 1993. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res. 53: 2830-2833.
24. IIDA, J., A.M. MEIJNE, R.C. SPIRO, et al. 1995. Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res. 55: 2177-2185.
25. SCHWARTZ, N. 2000. Biosynthesis and regulation of expression of proteoglycans. Front. Biosci. 5: D649-655.
26. NISHIYAMA, A, K.J. DAHLIN, J.T. PRINCE, et al. 1991. The primary structure of NG2, a novel membrane-spanning proteoglycan. J. Cell Biol. 114: 359-371.
27. PLUSCHKE, G., M. VANEK, A. EVANS, et al. 1996. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. USA 93: 9710-9715.
28. STALLCUP, W.B. 2002. The NG2 proteoglycan: past insights and future prospects. J. Neurocytol. 31: 423-435.
29. FANG, X., M. BURG, D. BARRITT, et al. 1999. Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol. Biol. Cell. 10: 3373-3387.
30. BÜRO, M., K. GRAKO & W. STALLCUP. 1998. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol. 177: 299-312.
31. EISENMANN, K.M., J.B. MCCARTHY, M.A. SIMPSON, et al. 1999. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat. Cell Biol. 1: 507-513.
32. LIU, S., D.A. CALDERWOOD & M.H. GINSBERG. 2000. Integrin cytoplasmic domain-binding proteins. J. Cell. Sci. 113: 3563-3571.
33. PARSONS, J.T., K.H. MARTIN, J.K. SLACK, et al. 2000. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19: 5606-5013.
34. 1 integrin-mediated melanoma cell adhesion. J. Biol. Chem. 273: 5955-5962.
35. CHEKENYA, M., M. HJELSTUEN, P.O. ENGER, et al. 2002. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 16: 586-588.
36. SCHLINGEMANN, R.O., F.J. RIETVELD, R.M. DE WAAL, et al. 1990. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am. J. Pathol. 136: 1393-1405.
37. RAJKUMAR, V.S., C. SUNDBERG, D.J. ABRAHAM, et al. 1999. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 42: 930-941.
38. FINLAY, G.J., B.C. BAGULEY & W.R. WILSON. 1984. A semi-automated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 139: 272-277.